QQQ   273.35 (+2.28%)
AAPL   142.34 (+3.00%)
MSFT   240.46 (+3.25%)
META   138.47 (+2.06%)
GOOGL   98.51 (+2.99%)
AMZN   116.33 (+2.95%)
TSLA   242.37 (-8.63%)
NVDA   124.96 (+2.94%)
NIO   15.51 (-1.65%)
BABA   80.67 (+0.85%)
AMD   66.05 (+4.25%)
T   15.98 (+4.17%)
MU   51.69 (+3.17%)
CGC   2.91 (+6.59%)
F   11.45 (+2.23%)
GE   63.54 (+2.63%)
DIS   97.11 (+2.95%)
AMC   6.84 (-1.87%)
PYPL   87.13 (+1.23%)
PFE   44.19 (+0.98%)
NFLX   238.86 (+1.45%)
QQQ   273.35 (+2.28%)
AAPL   142.34 (+3.00%)
MSFT   240.46 (+3.25%)
META   138.47 (+2.06%)
GOOGL   98.51 (+2.99%)
AMZN   116.33 (+2.95%)
TSLA   242.37 (-8.63%)
NVDA   124.96 (+2.94%)
NIO   15.51 (-1.65%)
BABA   80.67 (+0.85%)
AMD   66.05 (+4.25%)
T   15.98 (+4.17%)
MU   51.69 (+3.17%)
CGC   2.91 (+6.59%)
F   11.45 (+2.23%)
GE   63.54 (+2.63%)
DIS   97.11 (+2.95%)
AMC   6.84 (-1.87%)
PYPL   87.13 (+1.23%)
PFE   44.19 (+0.98%)
NFLX   238.86 (+1.45%)
QQQ   273.35 (+2.28%)
AAPL   142.34 (+3.00%)
MSFT   240.46 (+3.25%)
META   138.47 (+2.06%)
GOOGL   98.51 (+2.99%)
AMZN   116.33 (+2.95%)
TSLA   242.37 (-8.63%)
NVDA   124.96 (+2.94%)
NIO   15.51 (-1.65%)
BABA   80.67 (+0.85%)
AMD   66.05 (+4.25%)
T   15.98 (+4.17%)
MU   51.69 (+3.17%)
CGC   2.91 (+6.59%)
F   11.45 (+2.23%)
GE   63.54 (+2.63%)
DIS   97.11 (+2.95%)
AMC   6.84 (-1.87%)
PYPL   87.13 (+1.23%)
PFE   44.19 (+0.98%)
NFLX   238.86 (+1.45%)
QQQ   273.35 (+2.28%)
AAPL   142.34 (+3.00%)
MSFT   240.46 (+3.25%)
META   138.47 (+2.06%)
GOOGL   98.51 (+2.99%)
AMZN   116.33 (+2.95%)
TSLA   242.37 (-8.63%)
NVDA   124.96 (+2.94%)
NIO   15.51 (-1.65%)
BABA   80.67 (+0.85%)
AMD   66.05 (+4.25%)
T   15.98 (+4.17%)
MU   51.69 (+3.17%)
CGC   2.91 (+6.59%)
F   11.45 (+2.23%)
GE   63.54 (+2.63%)
DIS   97.11 (+2.95%)
AMC   6.84 (-1.87%)
PYPL   87.13 (+1.23%)
PFE   44.19 (+0.98%)
NFLX   238.86 (+1.45%)

Corcept Therapeutics - CORT Stock Forecast, Price & News

$26.06
+0.42 (+1.64%)
(As of 10/3/2022 03:59 PM ET)
Add
Compare
Today's Range
$25.42
$26.29
50-Day Range
$24.70
$29.12
52-Week Range
$15.82
$29.93
Volume
27,620 shs
Average Volume
802,895 shs
Market Capitalization
$2.79 billion
P/E Ratio
27.72
Dividend Yield
N/A
Price Target
$32.00

Corcept Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
22.9% Upside
$32.00 Price Target
Short Interest
Bearish
18.45% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.43
Upright™ Environmental Score
News Sentiment
1.88mentions of Corcept Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$10.52 M Sold Last Quarter
Proj. Earnings Growth
11.36%
From $0.88 to $0.98 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.40 out of 5 stars

Medical Sector

288th out of 1,093 stocks

Pharmaceutical Preparations Industry

126th out of 548 stocks

CORT stock logo

About Corcept Therapeutics (NASDAQ:CORT) Stock

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.

Receive CORT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corcept Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CORT Stock News Headlines

Corcept Therapeutics (CORT) Q2 Earnings Lag Estimates
Corcept Therapeutics - Drug Development
CORT Crosses Above Average Analyst Target
See More Headlines
Receive CORT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corcept Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CORT Company Calendar

Last Earnings
8/03/2022
Today
10/03/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:CORT
CUSIP
21835210
Employees
238
Year Founded
1998

Price Target and Rating

Average Stock Price Forecast
$32.00
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$30.00
Forecasted Upside/Downside
+22.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$112.51 million
Pretax Margin
33.66%

Debt

Sales & Book Value

Annual Sales
$365.98 million
Cash Flow
$1.02 per share
Book Value
$3.26 per share

Miscellaneous

Free Float
87,183,000
Market Cap
$2.79 billion
Optionable
Optionable
Beta
0.53

Social Links


Key Executives

  • Dr. Joseph K. Belanoff M.D. (Age 65)
    Co-Founder, Pres, CEO & Director
    Comp: $1.69M
  • Mr. Atabak Mokari (Age 45)
    CFO & Treasurer
    Comp: $687.98k
  • Dr. Hazel Hunt Ph.D. (Age 62)
    Chief Scientific Officer
    Comp: $826.67k
  • Mr. Sean MaduckMr. Sean Maduck (Age 45)
    Pres of Corcept Endocrinology
    Comp: $828.83k
  • Mr. Gary Charles Robb (Age 59)
    Chief Bus. Officer & Sec.
    Comp: $900.08k
  • Mr. Joseph Douglas LyonMr. Joseph Douglas Lyon (Age 43)
    Chief Accounting Officer
  • Dr. Christopher Shayne James M.D.
    Director of Investor Relations
  • Ms. Amy Flood
    Chief HR & Communications Officer
  • Donald E. Laferle
    Sr. VP
  • Dr. William Guyer Pharm.D. (Age 54)
    Chief Devel. Officer













CORT Stock - Frequently Asked Questions

Should I buy or sell Corcept Therapeutics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CORT shares.
View CORT analyst ratings
or view top-rated stocks.

What is Corcept Therapeutics' stock price forecast for 2022?

4 analysts have issued 12 month price objectives for Corcept Therapeutics' shares. Their CORT share price forecasts range from $30.00 to $35.00. On average, they anticipate the company's share price to reach $32.00 in the next twelve months. This suggests a possible upside of 22.7% from the stock's current price.
View analysts price targets for CORT
or view top-rated stocks among Wall Street analysts.

How have CORT shares performed in 2022?

Corcept Therapeutics' stock was trading at $19.80 at the start of the year. Since then, CORT shares have increased by 31.7% and is now trading at $26.07.
View the best growth stocks for 2022 here
.

When is Corcept Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our CORT earnings forecast
.

How were Corcept Therapeutics' earnings last quarter?

Corcept Therapeutics Incorporated (NASDAQ:CORT) released its earnings results on Wednesday, August, 3rd. The biotechnology company reported $0.24 earnings per share for the quarter, missing analysts' consensus estimates of $0.25 by $0.01. The biotechnology company had revenue of $103.39 million for the quarter, compared to analysts' expectations of $101.51 million. Corcept Therapeutics had a net margin of 28.75% and a trailing twelve-month return on equity of 25.53%.

What guidance has Corcept Therapeutics issued on next quarter's earnings?

Corcept Therapeutics issued an update on its FY 2022 earnings guidance on Wednesday, August, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $400.00 million-$430.00 million, compared to the consensus revenue estimate of $414.43 million.

What is Joseph K. Belanoff's approval rating as Corcept Therapeutics' CEO?

6 employees have rated Corcept Therapeutics Chief Executive Officer Joseph K. Belanoff on Glassdoor.com. Joseph K. Belanoff has an approval rating of 100% among the company's employees. This puts Joseph K. Belanoff in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Corcept Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corcept Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), CA (CA), Alibaba Group (BABA), BlackRock (BLK), Inovio Pharmaceuticals (INO), Pfizer (PFE) and Activision Blizzard (ATVI).

What is Corcept Therapeutics' stock symbol?

Corcept Therapeutics trades on the NASDAQ under the ticker symbol "CORT."

How do I buy shares of Corcept Therapeutics?

Shares of CORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Corcept Therapeutics' stock price today?

One share of CORT stock can currently be purchased for approximately $26.07.

How much money does Corcept Therapeutics make?

Corcept Therapeutics (NASDAQ:CORT) has a market capitalization of $2.79 billion and generates $365.98 million in revenue each year. The biotechnology company earns $112.51 million in net income (profit) each year or $0.94 on an earnings per share basis.

How many employees does Corcept Therapeutics have?

The company employs 238 workers across the globe.

How can I contact Corcept Therapeutics?

Corcept Therapeutics' mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The official website for the company is www.corcept.com. The biotechnology company can be reached via phone at (650) 327-3270, via email at cjames@corcept.com, or via fax at 650-327-3218.

This page (NASDAQ:CORT) was last updated on 10/3/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.